11.85

16.86% 1.71

Replimune Group Inc (REPL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$10.14

Offen:

$12.6

24-Stunden-Volumen:

2.21M

Relative Volume:

2.81

Marktkapitalisierung:

$911.93M

Einnahmen:

Nettoeinkommen (Verlust:

$-209.96M

KGV:

-3.75

EPS:

-3.16

Netto-Cashflow:

$-176.27M

1W Leistung:

+12.96%

1M Leistung:

-5.12%

6M Leistung:

+19.82%

1J Leistung:

+57.58%

1-Tages-Spanne:

$11.48

$13.13

1-Wochen-Bereich:

$10.05

$13.13

52-Wochen-Spanne:

$4.92

$17.00

Replimune Group Inc Stock (REPL) Company Profile

Firmenname

Replimune Group Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (685)

Telefon

(781) 222-9600

Adresse

500 UNICORN PARK, WOBURN, MA

Mitarbeiter

331

Twitter

@Replimune

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

REPL's Discussions on Twitter

Vergleichen Sie REPL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REPL Replimune Group Inc	11.85	911.93M	0	-209.96M	-176.27M	-3.16
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-28	Eingeleitet	ROTH MKM	Buy
2023-04-17	Fortgesetzt	Piper Sandler	Overweight
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-10-15	Fortgesetzt	BTIG Research	Buy
2020-11-17	Eingeleitet	BTIG Research	Buy
2020-11-02	Eingeleitet	Jefferies	Buy
2020-10-15	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-07-01	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-05-05	Eingeleitet	Barclays	Overweight
2019-09-04	Eingeleitet	ROTH Capital	Buy
2019-07-23	Eingeleitet	Chardan Capital Markets	Buy
2019-07-12	Hochstufung	JP Morgan	Neutral → Overweight
2019-07-08	Eingeleitet	H.C. Wainwright	Buy
2019-04-25	Eingeleitet	Wedbush	Outperform
2019-01-23	Herabstufung	JP Morgan	Overweight → Neutral
2018-08-14	Eingeleitet	JP Morgan	Overweight
2018-08-14	Eingeleitet	Leerink Partners	Outperform

Alle ansehen

Replimune Group Inc Aktie (REPL) Neueste Nachrichten

Jan 21, 2025

Barclays maintains Replimune stock with $17 target By Investing.com - Investing.com UK

Jan 21, 2025

Replimune stock soars on FDA priority review for melanoma treatment - MSN

Jan 21, 2025

Replimune stock price target raised to $27 by BMO Capital - Investing.com South Africa

Jan 21, 2025

Replimune Stock Soars 16% on FDA Priority Review for Advanced Me - GuruFocus.com

Jan 21, 2025

Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy - Yahoo Finance

Jan 21, 2025

Replimune stock soars on FDA priority review for melanoma treatment By Investing.com - Investing.com Australia

Jan 21, 2025

Replimune Group (NASDAQ:REPL) Shares Gap UpTime to Buy? - MarketBeat

Jan 21, 2025

Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga

Jan 21, 2025

FDA accepts Replimune's advanced melanoma therapy BLA - Investing.com

Jan 21, 2025

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma - The Manila Times

Jan 21, 2025

FDA Grants Priority Review to Replimune's Melanoma Treatment RP1, Breakthrough Therapy Status Secured - StockTitan

Jan 21, 2025

JPMorgan Chase & Co. Raises Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jan 21, 2025

Jan 17, 2025

Trend Tracker for (REPL) - Stock Traders Daily

Jan 17, 2025

Jan 16, 2025

Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology - MSN

Jan 16, 2025

Jan 14, 2025

Replimune Group (NASDAQ:REPL) Trading Down 6.6%Here's Why - MarketBeat

Jan 14, 2025

Jan 12, 2025

Barclays PLC Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jan 12, 2025

Barclays PLC Has $1.74 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Jan 12, 2025

Jan 11, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 11, 2025

Jan 10, 2025

Replimune Awards Equity Incentives to 30 New Hires, Including 253,820 Shares in Options and RSUs - StockTitan

Jan 10, 2025